title: Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
abstract: The hypothesis that clinical side effects of the aldose reductase inhibitor (ARI) sorbinil were related to its hydantoin ring led to a bioisosteric analysis and replacement of the hydantoin by a spiro hydroxy acetic acid moiety as in 40. These hydroxy acids, compared to hydantoins, showed a similar potency increase on chroman 2-methyl substitution, a similar orthogonal relationship of acidic to aromatic moieties, and similar ARI enantioselectivity. In this series the six-membered spiro hydroxy acetic acid anion array is a bioisostere for a spiro hydantoin anion and leads to ARIs with excellent in vivo activity. In vitro and in vivo activity was improved over 40 by chroman cis 2-methylation as in 4 and by aromatic 6,7-halogen substitution. Compounds with the best acute in vivo activity in rats were compared for chronic in vivo activity. The highest tissue levels and best chronic in vivo activities were found in the racemic 6,7-dichloro and 6-fluoro-7-chloro analogues 18 and 23. ARI activity was enantioselective for 58 and 60, the 2R,4R-enantiomers of 18 and 23. 7-Chloro-6-fluoro-cis-4-hydroxy-2(R)-methyl-chroman-4-acetic acid (60) was selected for phase 1 clinical trials and did not exhibit sorbinil-like hypersensitivity side effects.
authors.affiliation: Central Research Division, Pfizer Inc., Groton, Connecticut 06340.
authors.forename: C A
authors.initials: CA
authors.lastname: Lipinski
authors.forename: C E
authors.initials: CE
authors.lastname: Aldinger
authors.forename: T A
authors.initials: TA
authors.lastname: Beyer
authors.forename: J
authors.initials: J
authors.lastname: Bordner
authors.forename: D F
authors.initials: DF
authors.lastname: Burdi
authors.forename: D L
authors.initials: DL
authors.lastname: Bussolotti
authors.forename: P B
authors.initials: PB
authors.lastname: Inskeep
authors.forename: T W
authors.initials: TW
authors.lastname: Siegel
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D002839:Chromans / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006016:Glycolates / Q000737:chemistry*; D006801:Humans; D006827:Hydantoins / Q000737:chemistry*; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology; D048289:Imidazolidines; D008297:Male; D008968:Molecular Conformation; D015394:Molecular Structure; D051381:Rats; D011919:Rats, Inbred Strains; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014961:X-Ray Diffraction
chemical_list: D002839:Chromans; D006016:Glycolates; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; C031149:glycolic acid; C075250:7-chloro-6-fluoro-4-hydroxy-2-methylchroman-4-acetic acid; D013012:Sorbitol; D000449:Aldehyde Reductase; C026411:sorbinil